Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis.
Humans
Antiviral Agents
/ therapeutic use
Hepatitis C, Chronic
/ drug therapy
Hepacivirus
/ genetics
Genotype
Sustained Virologic Response
Drug Therapy, Combination
Sofosbuvir
/ therapeutic use
Treatment Outcome
Benzimidazoles
/ therapeutic use
Heterocyclic Compounds, 4 or More Rings
/ therapeutic use
Carbamates
/ therapeutic use
Clinical trial
Direct-acting antiviral
Hepatitis C virus
Meta-analysis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
21
03
2023
accepted:
10
09
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
30
9
2024
Statut:
epublish
Résumé
Direct-acting antivirals (DAAs) show high cure rates in treating chronic hepatitis C virus (HCV). However, the effect of DAAs on patients infected with genotype 2 (GT2) is difficult to determine despite the availability of several DAA regimens. A systematic search of six databases (PubMed, Embase, Cochrane Library, Web of Science, CNKI, and Clinicaltrial.gov) was conducted through April 20, 2022. We considered the sustained virological response 12 weeks after treatment (SVR12) as the efficacy outcome, and adverse events (AEs) as the safety outcome. By calculating the mean SVR12 and the proportion of AEs among patients, we considered the intervention effect for each DAA regimen. The random effect model was then used in all meta-analyses. This systematic review and meta-analysis aimed to summarize the evidence on efficacy and safety of DAAs in patients infected with HCV GT2. The Bayesian Markov Chain Monte Carlo (MCMC) network metanalysis was used to indirectly compare regimen in GT2 patients. Among 31 articles included (2,968 participants), consisting of 1,387 treatment-naive patients and 354 patients with cirrhosis. The overall pooled SVR12 rate was 94.62% (95% CI: 92.43-96.52%) among the participants who received all doses of treatment. Meta-analysis results of AEs revealed that fatigue was the most common AE (14.0%, 95% CI: 6.4-21.6%), followed by headache (13.1%, 95% CI: 9.2-17.1%), whereas death and serious adverse events were uncommon. We compared DAA-based treatments indirectly using meta-analysis and found the combination of Sofosbuvir plus Velpatasvir and Glecaprevir plus Pibrentasvir, each administered over a 12-week period, were identified as the most effective and relatively safe in managing chronic hepatitis C virus genotype 2 (HCV GT2) infection. Both treatments achieved a SVR12 of 100% (95% CI 99-100%).
Sections du résumé
BACKGROUND
BACKGROUND
Direct-acting antivirals (DAAs) show high cure rates in treating chronic hepatitis C virus (HCV). However, the effect of DAAs on patients infected with genotype 2 (GT2) is difficult to determine despite the availability of several DAA regimens.
METHODS
METHODS
A systematic search of six databases (PubMed, Embase, Cochrane Library, Web of Science, CNKI, and Clinicaltrial.gov) was conducted through April 20, 2022. We considered the sustained virological response 12 weeks after treatment (SVR12) as the efficacy outcome, and adverse events (AEs) as the safety outcome. By calculating the mean SVR12 and the proportion of AEs among patients, we considered the intervention effect for each DAA regimen. The random effect model was then used in all meta-analyses. This systematic review and meta-analysis aimed to summarize the evidence on efficacy and safety of DAAs in patients infected with HCV GT2. The Bayesian Markov Chain Monte Carlo (MCMC) network metanalysis was used to indirectly compare regimen in GT2 patients.
RESULTS
RESULTS
Among 31 articles included (2,968 participants), consisting of 1,387 treatment-naive patients and 354 patients with cirrhosis. The overall pooled SVR12 rate was 94.62% (95% CI: 92.43-96.52%) among the participants who received all doses of treatment. Meta-analysis results of AEs revealed that fatigue was the most common AE (14.0%, 95% CI: 6.4-21.6%), followed by headache (13.1%, 95% CI: 9.2-17.1%), whereas death and serious adverse events were uncommon.
CONCLUSIONS
CONCLUSIONS
We compared DAA-based treatments indirectly using meta-analysis and found the combination of Sofosbuvir plus Velpatasvir and Glecaprevir plus Pibrentasvir, each administered over a 12-week period, were identified as the most effective and relatively safe in managing chronic hepatitis C virus genotype 2 (HCV GT2) infection. Both treatments achieved a SVR12 of 100% (95% CI 99-100%).
Identifiants
pubmed: 39350091
doi: 10.1186/s12876-024-03414-5
pii: 10.1186/s12876-024-03414-5
doi:
Substances chimiques
Antiviral Agents
0
Sofosbuvir
WJ6CA3ZU8B
Benzimidazoles
0
Heterocyclic Compounds, 4 or More Rings
0
Carbamates
0
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
331Informations de copyright
© 2024. The Author(s).
Références
Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006.
doi: 10.1038/nrdp.2017.6
pubmed: 28252637
World Health Organization, Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. 2016. https://www.who.int/publications/i/item/WHO-HIV-2016.06
Polaris Observatory HCVC. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396–415.
doi: 10.1016/S2468-1253(21)00472-6
Asahina Y, Drafting Committee for Hepatitis Management Guidelines tJSoH. JSH guidelines for the management of Hepatitis C virus infection, 2019 update; protective effect of antiviral therapy against Hepatocarcinogenesis. Hepatol Res. 2020;50(7):775–90.
doi: 10.1111/hepr.13501
pubmed: 32298527
Chinese Society of Hepatology and Chinese Society of Infectious Diseases CMA. Guidelines for the prevention and treatment of hepatitis C (2019 version). J Clin Hepatol. 2019;35(12):2670–86.
Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and treating Hepatitis C virus infection. Hepatology. 2020;71(2):686–721.
doi: 10.1002/hep.31060
pubmed: 31816111
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176.
doi: 10.1016/S2468-1253(16)30181-9
Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–27.
doi: 10.1002/hep.26744
pubmed: 24115039
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–40.
doi: 10.3748/wjg.v22.i34.7824
pubmed: 27678366
pmcid: 5016383
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2016; 354:i4086.
Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579.
doi: 10.1186/s12913-014-0579-0
pubmed: 25413154
pmcid: 4310146
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
doi: 10.1136/bmj.l4898
pubmed: 31462531
Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
doi: 10.1136/bmj.i4919
pubmed: 27733354
pmcid: 5062054
Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):39.
doi: 10.1186/2049-3258-72-39
pubmed: 25810908
pmcid: 4373114
Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–60.
doi: 10.1136/ebmental-2019-300117
pubmed: 31563865
pmcid: 10231495
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
doi: 10.1136/bmj.327.7414.557
pubmed: 12958120
pmcid: 192859
Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018;38(Suppl 1Suppl 1):7–13.
doi: 10.1111/liv.13673
pubmed: 29427484
pmcid: 7713514
Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.
doi: 10.1056/NEJMoa1512610
pubmed: 26571066
Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17.
doi: 10.1056/NEJMoa1512612
pubmed: 26575258
Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, et al. Efficacy of 8 weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in patients with chronic HCV infection: 2 phase 3 Randomized trials. Gastroenterology. 2017;153(1):113–22.
doi: 10.1053/j.gastro.2017.03.047
pubmed: 28390869
Asselah T, Shafran SD, Bourgeois S, Lai CL, Mathurin P, Willems B, Nguyen MH, Davis MN, Huang KC, Svarovskaia E, et al. Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection. J Viral Hepat. 2019;26(10):1229–32.
doi: 10.1111/jvh.13159
pubmed: 31216086
Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17.
doi: 10.1056/NEJMoa1512612
pubmed: 26575258
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, et al. Sofosbuvir for Hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77.
doi: 10.1056/NEJMoa1214854
pubmed: 23607593
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.
doi: 10.1056/NEJMoa1214853
pubmed: 23607594
Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, et al. Sofosbuvir plus Ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762–8.
doi: 10.1111/jvh.12312
pubmed: 25196837
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, et al. Sofosbuvir and Ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.
doi: 10.1056/NEJMoa1316145
pubmed: 24795201
Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, Copans A, Rossaro L, Roy A, Le H, et al. Efficacy of Sofosbuvir Plus Ribavirin in Veterans with Hepatitis C Virus Genotype 2 infection, compensated cirrhosis, and multiple comorbidities. Clin Gastroenterol Hepatol. 2017;15(2):282–8.
doi: 10.1016/j.cgh.2016.05.024
pubmed: 27237429
Asahina Y, Itoh Y, Ueno Y, Matsuzaki Y, Takikawa Y, Yatsuhashi H, Genda T, Ikeda F, Matsuda T, Dvory-Sobol H, et al. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int. 2018;38(9):1552–61.
doi: 10.1111/liv.13685
pubmed: 29297980
Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67(2):505–13.
doi: 10.1002/hep.29510
pubmed: 28865152
Gane EJ, Hyland RH, Yang Y, Svarovskaia E, Stamm LM, Brainard DM, McHutchison JG, Stedman CAM. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 weeks in patients with Hepatitis C Virus genotype 2 infection. Gastroenterology. 2017;152(6):1366–71.
doi: 10.1053/j.gastro.2017.01.017
pubmed: 28137593
Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 weeks in patients with Hepatitis C Virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417–26.
doi: 10.1016/j.cgh.2017.09.027
pubmed: 28951228
Brown RS Jr., Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horvath G, Zuckerman E, Carrion BR, Rodriguez-Perez F, et al. Glecaprevir/pibrentasvir for 8weeks in treatment-naive patients with chronic HCV genotypes 1–6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72(3):441–9.
doi: 10.1016/j.jhep.2019.10.020
pubmed: 31682879
Wei L, Wang G, Alami NN, Xie W, Heo J, Xie Q, Zhang M, Kim YJ, Lim SG, Fredrick LM, et al. Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol. 2020;5(9):839–49.
doi: 10.1016/S2468-1253(20)30086-8
pubmed: 32682494
Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification of the best direct-acting antiviral regimen for patients with Hepatitis C Virus genotype 3 infection: a systematic review and network Meta-analysis. Clin Gastroenterol Hepatol. 2017;15(3):349–59.
doi: 10.1016/j.cgh.2016.10.034
pubmed: 27840182
Due OT, Chaikledkaew U, Genuino AJM, Sobhonslidsuk A, Thakkinstian A. Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6. Biomed Res Int. 2019;2301291.
Fawsitt CG, Vickerman P, Cooke G, Welton NJ. A cost-effectiveness analysis of shortened direct-acting antiviral treatment in genotype 1 noncirrhotic treatment-naive patients with chronic Hepatitis C Virus. Value Health. 2019;22(6):693–703.
doi: 10.1016/j.jval.2018.12.011
pubmed: 31198187
pmcid: 6588649
Pisaturo M, Russo A, Onorato L, Coppola N. Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis. Acta Biomed. 2019;90(2):187–96.
pubmed: 31124995
Asahina Y. JSH guidelines for the management of Hepatitis C virus infection, 2019 update; protective effect of antiviral therapy against Hepatocarcinogenesis. Hepatol Res. 2020;50(7):775–90.
doi: 10.1111/hepr.13501
pubmed: 32298527
Australian Institute of Health and Welfare. Cancer data in Australia. Canberra: AIHW (AIHW Cat. No. CAN 122). 2020. https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/about
Liu H, Yang XL, Dong ZR, Chen ZQ, Hong JG, Wang DX, Li T. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(9):1654–65.
doi: 10.1111/jgh.15915
pubmed: 35722709
Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, Tonizzo M, Gitto S, Andreone P, Gattei V. A review on extrahepatic manifestations of Chronic Hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses. 2021;13(11).
Adinolfi LE, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, Rinaldi L, Calvaruso V, Staiano L, Di Marco V, et al. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: a prospective multicentre study. Atherosclerosis. 2020;296:40–7.
doi: 10.1016/j.atherosclerosis.2020.01.010
pubmed: 32005004
Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology. 2017;65(5):1770–1.
doi: 10.1002/hep.28981
pubmed: 27943361
Bohorquez H, Velez JCQ, Lusco M, Scheuermann J, Cohen AJ. Hepatitis C-associated focal proliferative glomerulonephritis in an aviremic recipient of a hepatitis C-positive antibody donor liver. Am J Transpl. 2021;21(8):2895–9.
doi: 10.1111/ajt.16565
Chen YC, Tseng CW, Tseng KC. Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents. Med (Baltim). 2020;99(19):e20156.
doi: 10.1097/MD.0000000000020156
Ding YJ, Lu CK, Chen WM, Tung SY, Wei KL, Shen CH, Hsieh YY, Yen CW, Chang KC, Chiu WN, et al. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: a real-world effectiveness analysis. J Gastroenterol Hepatol. 2021;36(10):2911–6.
doi: 10.1111/jgh.15546
pubmed: 33978973
Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L Jr., Hu Y, et al. Exploratory trial of ombitasvir and ABT-450/r with or without Ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70(2):197–205.
doi: 10.1016/j.jinf.2014.09.008
pubmed: 25246359
Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hezode C, Inada Y, Heo J, et al. A randomized, controlled study of peginterferon lambda-1a/ribavirin +/- daclatasvir for hepatitis C virus genotype 2 or 3. Springerplus. 2016;5(1):1365.
doi: 10.1186/s40064-016-2920-z
pubmed: 27588258
pmcid: 4990525
Brown A, Hezode C, Zuckerman E, Foster GR, Zekry A, Roberts SK, Lahser F, Durkan C, Badshah C, Zhang B, et al. Efficacy and safety of 12 weeks of elbasvir +/- grazoprevir +/- Ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: the C-SCAPE study. J Viral Hepat. 2018;25(5):457–64.
doi: 10.1111/jvh.12801
pubmed: 29152828
Dore GJ, Lawitz E, Hezode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, et al. Daclatasvir plus Peginterferon and Ribavirin is noninferior to Peginterferon and Ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology. 2015;148(2):355–66. e351.
doi: 10.1053/j.gastro.2014.10.007
pubmed: 25311593
Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, et al. Sofosbuvir with Velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 Hepatitis C virus infection: a Randomized Trial. Ann Intern Med. 2015;163(11):818–26.
doi: 10.7326/M15-1000
pubmed: 26551051
Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, et al. Efficacy of Sofosbuvir plus Ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149(6):1462–70.
doi: 10.1053/j.gastro.2015.07.043
pubmed: 26248087
Gane EJ, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, Gordon SC, Bernstein D, Everson G, Rodriguez-Torres M, et al. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in patients with Hepatitis C Virus genotype 2, 3, 4, or 6 infections in an Open-Label, phase 2 trial. Gastroenterology. 2016;151(5):902–9.
doi: 10.1053/j.gastro.2016.07.038
pubmed: 27486033
Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, et al. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without Ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017;2(11):814–23.
doi: 10.1016/S2468-1253(17)30163-2
pubmed: 28802814
Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, et al. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. J Viral Hepat. 2019;26(9):1127–38.
doi: 10.1111/jvh.13132
pubmed: 31108015
Lawitz E, Poordad F, Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, et al. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. J Viral Hepat. 2019;26(6):675–84.
doi: 10.1111/jvh.13079
pubmed: 30739366
Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, et al. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4(2):127–34.
doi: 10.1016/S2468-1253(18)30343-1
pubmed: 30555048
Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, et al. Sofosbuvir-Velpatasvir plus Ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int. 2018;12(4):356–67.
doi: 10.1007/s12072-018-9878-6
pubmed: 30030720
Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, Mao Q, Jiang X, Wang C, Zhang Y, et al. Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis. J Viral Hepat. 2020;27(1):45–51.
doi: 10.1111/jvh.13208
pubmed: 31520460
Shafran SD, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Pilot-Matias T, Pothacamury RK, Fu B, Cohen E, et al. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without Ribavirin (QUARTZ II-III). J Viral Hepat. 2018;25(2):118–25.
doi: 10.1111/jvh.12782
pubmed: 28833938
Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, Wen X, Hu J, Wang X, Wu X, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 trial. Liver Int. 2020;40(11):2685–93.
doi: 10.1111/liv.14633
pubmed: 33047868
pmcid: 7702130
Hua R, Kong F, Wen X, Xiong Q, Chen J, Meng C, Ma H, Tan Y, Huang Y, Jiang Y, et al. Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: an open-label, phase 2 study. J Viral Hepat. 2022;29(6):455–64.
doi: 10.1111/jvh.13650
pubmed: 35080256